160 related articles for article (PubMed ID: 17989864)
1. [Update on the prevention of thromboembolic phenomena in atrial fibrillation].
Montagna M R; Asenjo G R; Morris C R; Ortiz O M; Cereceda B M
Rev Med Chil; 2007 Aug; 135(8):1048-55. PubMed ID: 17989864
[TBL] [Abstract][Full Text] [Related]
2. [Preventing cerebrovascular accidents during atrial fibrillation].
Ederhy S; Meuleman C; Hammoudi N; Janower S; Boccara F; Cohen A
Presse Med; 2005 Oct; 34(18):1315-24. PubMed ID: 16269996
[TBL] [Abstract][Full Text] [Related]
3. Non-Vitamin K Antagonist Oral Anticoagulants and Antiplatelet Therapy for Stroke Prevention in Patients With Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials.
Kumar S; Danik SB; Altman RK; Barrett CD; Lip GY; Chatterjee S; Roubin GS; Natale A; Danik JS
Cardiol Rev; 2016; 24(5):218-23. PubMed ID: 26274538
[TBL] [Abstract][Full Text] [Related]
4. New pharmacologic approaches to prevent thromboembolism in patients with atrial fibrillation.
Hammwöhner M; D'Alessandro A; Wolfram O; Goette A
Curr Vasc Pharmacol; 2007 Jul; 5(3):211-9. PubMed ID: 17627564
[TBL] [Abstract][Full Text] [Related]
5. Alternatives to warfarin for thromboembolism prophylaxis in nonrheumatic atrial fibrillation.
Artang R; Vidaillet H
J Interv Card Electrophysiol; 2004; 10 Suppl 1():33-44. PubMed ID: 14739738
[TBL] [Abstract][Full Text] [Related]
6. [Prevention of thromboembolism in atrial fibrillation].
Aguiar C
Rev Port Cardiol; 2012 Apr; 31 Suppl 1():17-26. PubMed ID: 22541031
[TBL] [Abstract][Full Text] [Related]
7. Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter.
Segal JB; McNamara RL; Miller MR; Powe NR; Goodman SN; Robinson KA; Bass EB
Cochrane Database Syst Rev; 2001; (1):CD001938. PubMed ID: 11279741
[TBL] [Abstract][Full Text] [Related]
8. Contemporary measures to reduce the risk of embolic events in patients with atrial fibrillation.
El Kadri M; Sharaf Dabbagh G; Oral H
Future Cardiol; 2015; 11(6):635-43. PubMed ID: 26609866
[TBL] [Abstract][Full Text] [Related]
9. [Atrial fibrillation and thromboembolic events prevention. State of the art].
Matteoli S; Trappolini M; Chillotti FM
Minerva Cardioangiol; 2001 Feb; 49(1):1-13. PubMed ID: 11279381
[TBL] [Abstract][Full Text] [Related]
10. Update on pharmacologic approaches to prevent thromboembolism in atrial fibrillation: are thrombin and factor Xa inhibitors the ultimate answer?
Wolfram O; Hammwoehner M; Gramley F; Goette A
Curr Vasc Pharmacol; 2011 May; 9(3):350-7. PubMed ID: 21143166
[TBL] [Abstract][Full Text] [Related]
11. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.
; Bousser MG; Bouthier J; Büller HR; Cohen AT; Crijns H; Davidson BL; Halperin J; Hankey G; Levy S; Pengo V; Prandoni P; Prins MH; Tomkowski W; Torp-Pedersen C; Wyse DG
Lancet; 2008 Jan; 371(9609):315-21. PubMed ID: 18294998
[TBL] [Abstract][Full Text] [Related]
12. [Anticoagulation in cardioversion of atrial fibrillation. Current status and outlook for the future].
Schimpf T; Stellbrink C
Med Klin (Munich); 2003 Feb; 98(2):91-5. PubMed ID: 12601533
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of percutaneous left atrial appendage closure to prevent thromboembolic events in atrial fibrillation patients with high stroke and bleeding risk.
Seeger J; Bothner C; Dahme T; Gonska B; Scharnbeck D; Markovic S; Rottbauer W; Wöhrle J
Clin Res Cardiol; 2016 Mar; 105(3):225-9. PubMed ID: 26318322
[TBL] [Abstract][Full Text] [Related]
14. Atrial fibrillation and anticoagulation.
Garnier LF; Rouesnel P; Espitalier F
Arch Mal Coeur Vaiss; 2004 Oct; 97(10):1001-5. PubMed ID: 16008178
[TBL] [Abstract][Full Text] [Related]
15. Single Antiplatelet Therapy Following Left Atrial Appendage Closure in Patients With Contraindication to Anticoagulation.
Rodriguez-Gabella T; Nombela-Franco L; Regueiro A; Jiménez-Quevedo P; Champagne J; O'Hara G; Bernier M; Macaya C; Rodés-Cabau J
J Am Coll Cardiol; 2016 Oct; 68(17):1920-1921. PubMed ID: 27765196
[No Abstract] [Full Text] [Related]
16. [Elimination of the left atrial appendage in the prevention of thromboembolic events in patients with atrial fibrillation].
Gancarczyk U; Przewłocki T; Podolec P; Komar M
Wiad Lek; 2019; 72(9 cz 2):1829-1833. PubMed ID: 31622274
[TBL] [Abstract][Full Text] [Related]
17. [Prevention of thromboembolism in non-rheumatic atrial fibrillation: an update].
Pengo V; De Caterina R
Ital Heart J Suppl; 2001 Sep; 2(9):972-9. PubMed ID: 11675834
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of catheter-based left atrial appendage closure in patients with contraindications for long-term anticoagulation.
Seidel A; Parwani AS; Krackhardt F; Huemer M; Attanasio P; Haverkamp W; Pieske B; Boldt LH
Minerva Cardioangiol; 2017 Dec; 65(6):545-552. PubMed ID: 28565887
[TBL] [Abstract][Full Text] [Related]
19. Direct thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillation.
Katira R; Chauhan A; More RS
Postgrad Med J; 2005 Jun; 81(956):370-5. PubMed ID: 15937202
[TBL] [Abstract][Full Text] [Related]
20. Use of oral anticoagulants in complex clinical situations with atrial fibrillation.
Gullón A; Sánchez Fuentes D; López-de-Sá E; Martí-Almor J; Barón-Esquivias G; Jiménez López J; Del Mar Contreras Muruaga M; Suárez Fernández C
Med Clin (Barc); 2018 Jun; 150 Suppl 1():8-24. PubMed ID: 30502871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
